Abstract :
The SARS‐CoV‐ 2/Covid-19 Coronavirus is currently endemic throughout the world. The comorbidities of Covid-19 with the highest percentage reaching 50.5% are hypertension. Hypertension included in Non-Communicable Diseases (NCD) is generally chronic. It can reduce the sufferer’s immune system gradually and is very susceptible to infections, including those caused by viral infections, one of which is the SARS-CoV-2 virus or commonly called COVID-19. Therefore, patients with NCD, especially hypertension, are encouraged to increase immunity and body immunity to avoid virus infection. Currently, nanoparticles, especially Nanogold and Nanosilver, are taking place very rapidly in the health sector because gold and silver nanoparticles have various benefits such as antioxidants, antivirals, and antibacterials. After being proven effective in dealing with leprosy patients in Surabaya, especially in terms of increasing immunity. Now Nanogold-Nanosilver was developed with the hope to help relieve Covid-19 sufferers through increasing the body’s immune system because if the body’s immune system decreases, the virus will quickly enter the body. In this study, Nanogold and Nanosilver were developed into a health water drink that volunteers can drink every day. Volunteers are people affected by Covid-19 in the Karanganyar area of Surabaya. This study uses a one-group pretest-posttest design. The data collection is carried out through direct observation and interviews with people affected by Covid-19 regularly every week. Then the data analysed using a paired T-test on the SPSS application. And obtained a P-value of 0.000, which means that there is an effect of nanogold-nanosilver for increase body immunity.
Keywords :
COVID-19, hypertension, Immunity, nanogold, nanosilverReferences :
1. A. Gunawan, K. Prahasanti, and M. R. Utama, “Pengaruh Komorbid Hipertensi Terhadap Severitas Pasien Yang Terinfeksi Covid 19,” J. Implementa Husada, vol. 1, no. 2, p. 136, 2020, doi: 10.30596/jih.v1i2.4972.
2. H. A. Willim, I. Ketaren, and A. I. Supit, “Dampak Coronavirus Disease 2019 terhadap Sistem Kardiovaskular,” e-CliniC, vol. 8, no. 2, pp. 237–245, 2020, doi: 10.35790/ecl.8.2.2020.30540.
3. R. Dhand and J. Li, “Coughs and Sneezes: Their Role in Transmission of Respiratory Viral Infections, including SARS-CoV-2,” Am. J. Respir. Crit. Care Med., vol. 202, no. 5, pp. 651–659, 2020, DOI: 10.1164/rccm.202004-1263PP.
4. D. Larasati, “PENINGKATAN INFORMASI PENYAKIT DENGAN KOMORBID HIPERTENSI PADA MASA PANDEMI COVID-19 DI PUSKESMAS PIYUNGAN The Information Improvment of Komorbid Hypertension Disease on The COVID-19 Pandemic on The Community Health Center of Piyungan,” vol. 3, no. 1, pp. 21–25, 2021.
5. P. ANGGRAINI, R. RUSDI, R. RUSDI, R. RUSDI, and E. I. ILYAS, “KADAR Na+, K+, Cl-, DAN KALSIUM TOTAL SERUM DARAH SERTA HUBUNGANNYA DENGAN TEKANAN DARAH PADA PENDERITA HIPERTENSI,” Bioma, vol. 11, no. 1, p. 50, 2015, doi: 10.21009/bioma11(1).6.
6. D. S. Aryantiningsih and J. B. Silaen, “Kejadian Hipertensi Pada Masyarakat Di Wilayah Kerja Puskesmas Harapan Raya Pekanbaru,” J. Ipteks Terap., vol. 12, no. 1, p. 64, 2018, doi: 10.22216/jit.2018.v12i1.1483.
7. C. Gao et al., “Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study,” Eur. Heart J., vol. 41, no. 22, pp. 2058–2066, 2020, doi: 10.1093/eurheartj/ehaa433.
8. B. B. Tiksnadi, N. Sylviana, A. I. Cahyadi, and A. C. Undarsa, “Olahraga Rutin untuk Meningkatkan Imunitas Pasien Hipertensi Selama Masa Pandemi COVID-19,” Indones. J. Cardiol., vol. 41, no. 2, pp. 113–119, 2020,
doi: 10.30701/ijc.1016.
9. H. Alfhad et al., “Dampak Infeksi SARS-Cov-2 Terhadap Penderita Hipertensi The Impact of SARS-Cov-2 infection on patients with hypertension,” Major. J., vol. 9, no. April, pp. 1–5, 2020.
10. J. T. Mesin et al., “PENINGKATAN KESEHATAN PADA REHABILITASI KUSTA DENGAN NANOGOLD-NANOSILVER HASIL PENELITIAN LPPM-UNESA Di kompleks Pondok Sosial Babat Jerawat Kecamatan Benowo ada sekitar 130 jiwa penghuni . 34 diantaranya anak-anak dan remaja . Mereka semua sehat tidak te,” pp. 688–695.
11. A. M. A. Moshed, M. K. I. Sarkar, and M. A. Khaleque, “The Application of Nanotechnology in Medical Sciences: New Horizon of Treatment,” Am. J. Biomed. Sci., vol. 9, no. 1, pp. 1–14, 2017, DOI: 10.5099/aj170100001.
12. U. Journal and K. Kunci, “PENGARUH PENAMBAHAN NANOGOLD TERHADAP AKTIVITAS ANTIOKSIDAN EKSTRAK GAMBIR ( Uncaria gambir Roxb . ) EFFECT OF NANOGOLD ADDITION TOWARD ANTIOXIDANT ACTIVITY OF EXTRACT GAMBIR ( Uncaria gambir Roxb . ) Dia Novita Sari dan TitikTaufikurohmah * Department of,” vol. 8, no. 1, 2019.
13. M. A. Amiruddin and T. Taufikurrohmah, “SINTESIS DAN KARAKTERISASI NANOPARTIKEL EMAS MENGGUNAKAN MATRIKS BENTONIT SEBAGAI MATERIAL PEREDAM RADIKAL BEBAS DALAM KOSMETIK,” UNESA J. Chem. Vol. 2, No. 1, January 2013, vol. 2, no. 1, pp. 68–75, 2013.
14. T. Taufikurohmah, D. Soepardjo, H. Armadianto, and R. Rusmini, “Synthesis and Characterisation of Nanogold and Nanosilver as Leprosy Drug Candidates and Their Activity Tests in Leprosy Patients; Case Study,” vol. 95, no. Miseic, pp. 22–27, 2020, DOI: 10.2991/miseic-19.2019.6.
15. D. R. Fauzan et al., “Hipertensi Dan Inflamasi : Sebuah Perspektif Ke Depan Untuk Target Terapi Baru Hypertension And Inflammation : A Future Perspective For New Target Therapy,” vol. 4, pp. 135–146, 2020.
16. S. B. Brosnahan, A. H. Jonkman, M. C. Kugler, J. S. Munger, and D. A. Kaufman, “Covid-19 and respiratory system disorders current knowledge, future clinical and translational research questions,” Arterioscler. Thromb. Vasc. Biol., no. November, pp. 2586–2597, 2020, DOI: 10.1161/ATVBAHA.120.314515.
17. S. YANTI, PARADIKSA, “PERILAKU CERDIK PENDERITA HIPERTENSI DIMASA PANDEMI COVID 19,” J. Keperawatan, vol. 13, no. 1, pp. 213–226, 2021.
18. A. Lia, Irwan, and F. Hiola, “Analysis of Clinical Symptoms and Immune Enhancement to Prevent COVID-19 Disease,” JAMBURA J. Heal. Sci. Res., vol. 2, no. 2, pp. 71–76, 2020.
19. J. A. Park et al., “Gold nanoparticles functionalised by Gd-complex of DTPA-bis(amide) conjugate of glutathione as an MRI contrast agent,” Bioorganic Med. Chem. Lett., vol. 18, no. 23, pp. 6135–6137, 2008,
DOI: 10.1016/j.bmcl.2008.10.017.
20. L. A. Dykman and N. G. Khlebtsov, “Immunological properties of gold nanoparticles,” Chem. Sci., vol. 8, no. 3, pp. 1719–1735, 2017, DOI: 10.1039/c6sc03631g.
21. L. A. Dykman and N. G. Khlebtsov, “Gold Nanoparticles in Biology and Medicine: Recent Advances and Prospects,” Acta Naturae, vol. 3, no. 2, pp. 34–55, 2011, DOI: 10.32607/20758251-2011-3-2-34-56.
22. N. E. Damayanti and T. Taufikurohmah, “PEMANFAATAN NANOSILVER SEBAGAI ANTIBAKTERI DALAM FORMULASI WHITENING CREAM TERHADAP Staphylococcus aureus UTILIZATION OF NANOSILVER AS AN ANTIBACTERIAL IN THE WHITENING CREAM FORMULATION AGAINST Staphylococcus aureus Nurma Erlita Damayanti dan Titik Taufi,” UNESA J. Chem., vol. 8, no. 2, pp. 53–61, 2019.
23. P. Allawadhi et al., “Silver nanoparticle based multifunctional approach for combating COVID-19,” Sensors Int., vol. 2, no. June, p. 100101, 2021, DOI: 10.1016/j.sintl.2021.100101.
24. K. Arfi and T. Taufikurohmah, “Pemanfaatan Nanosilver Sebagai Antibakteri Dalam Sediaan Farmasi Krim Pelembab Mata Utilization Of Nanosilver As Antibacterial Substance In Pharmaceutical Preparation Of Moisturizing Eyes Cream,” UNESA J. Chem., vol. 6, no. 1, pp. 11–19, 2017.
25. A. I. Hashim, D. J. A. Al Falahy, D. S. S. Hussain, and D. N. K. Tektook, “Efficiency of silver nanoparticle against virus coronaviruses,” Ann. Trop. Med. Public Heal., vol. 23, no. 09, 2020, DOI: 10.36295/asro.2020.23938.
26. F. Pilaquinga, J. Morey, M. Torres, R. Seqqat, and M. de las N. Piña, “Silver nanoparticles as a potential treatment against SARS-CoV-2: A review,” Wiley Interdiscip. Rev. Nanomedicine Nanobiotechnology, no. July 2020, pp. 1–19, 2021, DOI: 10.1002/wnan.1707.
27. A. Salleh et al., “The potential of silver nanoparticles for antiviral and antibacterial applications: A mechanism of action,” Nanomaterials, vol. 10, no. 8, pp. 1–20, 2020, DOI: 10.3390/nano10081566.
28. L. Ge, Q. Li, M. Wang, J. Ouyang, X. Li, and M. M. Q. Xing, “Nanosilver particles in medical applications: Synthesis, performance, and toxicity,” Int. J. Nanomedicine, vol. 9, no. 1, pp. 2399–2407, 2014, DOI: 10.2147/IJN.S55015.
29. K. Naik and M. Kowshik, “The silver lining: towards the responsible and limited usage of silver,” J. Appl. Microbiol., vol. 123, no. 5, pp. 1068–1087, 2017, DOI: 10.1111/jam.13525.
30. Y. Imai et al., “Angiotensin-converting enzyme 2 protects from severe acute lung failure” Nature, vol. 436, no. 7047, pp. 112–116, 2005, DOI: 10.1038/nature03712.